Vedolizumab for inflammatory bowel disease: From randomized controlled trials to real-life evidence

doi:10.3748/wjg.v24.i23.2457

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 24, Issue 23

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (17477)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-2) series, Tables (1-2) series.

Item

Count

PDF

1366

WORD

397

HTML

12126

Figures (1-2)

604

Tables (1-2)

244

Sum=14737

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

1123

Download

1617

Sum=2740

Jun 21, 2018 (publication date) through Nov 4, 2024

Times Cited of This Article

Times Cited (64)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Minireviews

World J Gastroenterol. Jun 21, 2018; 24(23): 2457-2467
Published online Jun 21, 2018. doi: 10.3748/wjg.v24.i23.2457

Full Size Figure Download Figure

Figure 1 Vedolizumab targets the α4β7 integrin, preventing leucocyte translocation from the blood into the inflamed gut tissue. MadCAM-1: Mucosal addressin cell adhesion molecule.

Citation: Scribano ML. Vedolizumab for inflammatory bowel disease: From randomized controlled trials to real-life evidence. World J Gastroenterol 2018; 24(23): 2457-2467
URL: https://www.wjgnet.com/1007-9327/full/v24/i23/2457.htm
DOI: https://dx.doi.org/10.3748/wjg.v24.i23.2457